Article No
ASJ-QL5XG8-200
AKT1
Anti-AKT1 antibody (60-140 aa) [1E11]
Antibodies Primary
Specifications
| Application | IF, IHC |
| Article No | ASJ-QL5XG8-200 |
| Biosite Brand | Biosite |
| Country Availability | all |
| Clone | 1E11 |
| Clone Type | monoclonal |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Description | Anti-AKT1 antibody (60-140 aa) [1E11] |
| Recommended Dilution | IF 1:50-200, IHC 1:100-200 |
| Supplier | Nordic Biosite |
| Entrez Gene ID | 207 |
| Gene Symbol | AKT1 |
| Immunogen | Synthetic peptide of AKT at the amino acid range of 60-140 |
| Isotype | IgG1 |
| Localization | Cytoplasm. Nucleus. Cell membrane. Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus. Colocalizes with WDFY2 in intracellular vesicles . |
| Notes | Mouse monoclonal against AKT |
| Alias Names | Anti-Rac-Alpha Serine/Threonine-Protein Kinase antibody,Anti-Protein Kinase B antibody,Anti-Pkb antibody,Anti-Protein Kinase B Alpha antibody,Anti-Pkb Alpha antibody,Anti-Proto-Oncogene C-Akt antibody,Anti-Rac-Pk-Alpha antibody,Anti-AKT1 PKB RAC antibody |
| Previous Article No | ASJ-F004EF |
| Product Type | Antibodies Primary |
| Protocol | IHC 1:100-200 |
| Purification | Affinity Purified |
| Size | 200ug |
| Source / Host | mouse |
| Species Reactivity | human, mouse, rat |
| Storage | -20°C |
| Substrate / Buffer | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Technical Specifications | Mouse monoclonal against AKT |
| Tissue Specificity | Expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages. |
| UniProt Number | P31749 |
| Product Page Updated | 2024-04-18T09:14:23.014Z |
